

Message

From: Richard E. Engler, Ph.D. [rengler@actagroup.com]
Sent: 6/2/2021 10:11:51 PM
To: Henry, Tala [Henry.Tala@epa.gov]
CC: Le, Madison [Le.Madison@epa.gov]; Edelstein, Rebecca [Edelstein.Rebecca@epa.gov]; Malagon, Hector [Malagon.Hector@epa.gov]; Barron, Emily [ebarron@guardian.com]; Lee, Beth [Beth.Lee@kochind.com]; 'Bowman, Heather S' [Heather.Bowman@kochps.com]; lbergeson@lawbc.com
Subject: RE: PMN delay

Thanks.

RICHARD E. ENGLER, PH.D.
DIRECTOR OF CHEMISTRY

ACTA ASIA | EUROPE | THE AMERICAS
2200 Pennsylvania Avenue, NW, Suite 100W | Washington, D.C. 20037
T: 202-557-3808 | F: 202-557-3836 | actagroup.com

From: Henry, Tala <Henry.Tala@epa.gov>
Sent: Wednesday, June 2, 2021 10:15 AM
To: Richard E. Engler, Ph.D. <rengler@actagroup.com>
Cc: Le, Madison <Le.Madison@epa.gov>; Edelstein, Rebecca <Edelstein.Rebecca@epa.gov>; Malagon, Hector <Malagon.Hector@epa.gov>; Barron, Emily <ebarron@guardian.com>; Lee, Beth <Beth.Lee@kochind.com>; 'Bowman, Heather S' <Heather.Bowman@kochps.com>; Lynn L. Bergeson <lbergeson@lawbc.com>
Subject: [EXTERNAL] RE: PMN delay

Rich,
Madison will look into the basis for dealy and get back to you.
Thanks for bring to my attention.
Tala

Tala R. Henry, Ph.D.
Deputy Director
Office of Pollution Prevention & Toxics

T: 202-564-2959
E: henry.tala@epa.gov

From: Richard E. Engler, Ph.D. <rengler@actagroup.com>
Sent: Wednesday, June 2, 2021 10:06 AM
To: Henry, Tala <Henry.Tala@epa.gov>
Cc: Le, Madison <Le.Madison@epa.gov>; Edelstein, Rebecca <Edelstein.Rebecca@epa.gov>; Malagon, Hector <Malagon.Hector@epa.gov>; Barron, Emily <ebarron@guardian.com>; Lee, Beth <Beth.Lee@kochind.com>; 'Bowman, Heather S' <Heather.Bowman@kochps.com>; lbergeson@lawbc.com
Subject: FW: PMN delay

Tala:

It has been over a month since Guardian reached out to NCD on P-20-0181 and there has been no response. Guardian is still waiting for any version of a health report or a teleconference with the health assessor so that Guardian can move forward with this case.

This is not a case in which the health report was complete and additional information was submitted; as far as Guardian is aware, a health report has yet to be generated. The February submission was to add context to what had been submitted previously, but we still do not have a quantitative view on EPA's potential health concerns.

Rich

RICHARD E. ENGLER, PH.D.
DIRECTOR OF CHEMISTRY

ACTA ASIA | EUROPE | THE AMERICAS
2200 Pennsylvania Avenue, NW, Suite 100W | Washington, D.C. 20037
T: 202-557-3808 | F: 202-557-3836 | actagroup.com

From: Richard E. Engler, Ph.D. <rengler@actagroup.com>
Sent: Friday, April 30, 2021 6:31 PM
To: 'Le, Madison' <Le.Madison@epa.gov>
Cc: 'Edelstein, Rebecca' <Edelstein.Rebecca@epa.gov>; 'Malagon, Hector' <Malagon.Hector@epa.gov>; 'Barron, Emily' <ebarron@guardian.com>; 'Lee, Beth' <Beth.Lee@kochind.com>; 'Bowman, Heather S' <Heather.Bowman@kochps.com>
Subject: PMN delay

Madison:

Guardian submitted P-20-0181 on September 11, 2020. According to EPA's website, the scoping meeting occurred on October 20, 2020. After a discussion with Hector Malagon regarding the potential health concerns that OPPT might express in a health report, Guardian prepared an additional explanation of its view that health risk would be minimal; this document was submitted February 2, 2021.

Guardian understands how overworked the New Chemicals Division's health assessors are. If a completed health report is not forthcoming because of other obligations, Guardian would very much like to discuss the health assessor's view of the updated health explanation so that Guardian can address any concerns that remain.

Please advise if Guardian can schedule a teleconference with the PMN review team (especially the health assessor) or when Guardian can expect a health report.

Rich

RICHARD E. ENGLER, PH.D.
DIRECTOR OF CHEMISTRY

ACTA ASIA | EUROPE | THE AMERICAS
2200 Pennsylvania Avenue, NW, Suite 100W | Washington, D.C. 20037
T: 202-557-3808 | F: 202-557-3836 | actagroup.com